Adaptyv is building an automated lab that lets AI agents run biology experiments. We are entering the era of agentic science where AI models can now design novel proteins, propose hypotheses, and iterate on experimental results.
About Us Harmattan AI is a next-generation defense prime building autonomous and scalable defense systems. Following the close of a $200M Series B, valuing the company at $1.4 billion, we are expanding our teams and capabilities
Giotto.ai is a Switzerland-based AI company building intelligence systems for Switzerland and Europe. Our mission is to build AI capabilities that enable Switzerland and Europe to preserve strategic independence, cultural identity, and core values while achieving
Giotto.ai is a Switzerland-based AI company building intelligence systems for Switzerland and Europe. Our mission is to build AI capabilities that enable Switzerland and Europe to preserve strategic independence, cultural identity, and core values while achieving
Adaptyv is building an automated lab that lets AI agents run biology experiments. We’re entering the era of agentic science where AI models can now design novel proteins, propose hypotheses, and iterate on experimental results. But
Adaptyv is building an automated lab thats let AI agents run biology experiments. Were entering the era of agentic science where AI models can now design novel proteins, propose hypotheses, and iterate on experimental results. But
Adaptyv is building an automated lab that lets AI agents run biology experiments. We’re entering the era of agentic science where AI models can design novel proteins, propose hypotheses, and iterate on experimental results, but they
Adaptyv is building an automated lab that’s let AI agents run biology experiments. We’re entering the era of agentic science where AI models can now design novel proteins, propose hypotheses, and iterate on experimental results. But
Adaptyv is building an automated lab that lets AI agents run biology experiments. Were entering the era of agentic science where AI models can now design novel proteins, propose hypotheses, and iterate on experimental results. But